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Abstract: Granular cell tumours (GCTs) are rare submucosal lesions, thought to develop from
Schwann cells, characterised by large polygonal cells with abundant lysosomes. The objectives of
this study are to investigate whether GCTs have an antigen-presenting cell (APC) phenotype or
a neural crest phenotype using immunohistochemistry and to compare expression profiles with
Schwannomas. Immunoreactivity to CD68, HLA-DR, CD163, CD40 and CD11c (APC phenotype)
and markers of neural crest cell (NCC) origin S100, SOX10, NSE and GAP43 in 23 cases of GCTs
and 10 cases of Schwannomas were evaluated. RT-qPCR was used to identify a possible NCC
developmental phenotype in 6 cases of GCTs. GAP43 was identified as a new NCC marker for GCTs,
and some evidence was found for an APC phenotype from CD68 and HLA-DR immunoreactivity.
RT-qPCR failed to identify an NCC developmental phenotype of GCTs, likely due to technical issues.
Keywords: granular cell tumour; schwannoma; immunohistochemistry; RT-PCR; neural crest markers;
APC markers
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1. Introduction

Investigation of the Molecular Profile

Granular cell tumours (GCT) are relatively rare soft tissue lesions of which the aetiology has been a focus of interest for many years. They are thought to be derived from cells
originating from the neural crest, specifically Schwann cells, based primarily on similarities
between the immunohistochemical biomarker staining profile of GCT and schwannomas.
GCTs usually present as a solitary benign lesion, although multifocal and malignant
cases are reported [1]. Approximately 50% of cases occur in the head and neck region,
most commonly in the tongue, representing 23% to 28% of all lesions and 65% to 85%
of intraoral lesions [1]. According to Allon et al., GCTs form 9.6% of benign tumours of
the oral mucosa [2]. They present, most commonly, in the fourth to sixth decades, with a
predilection for females over males of 2:1 [3]. Multiple lesions occur in 2–10% of cases [4].
GCTs are slow-growing indolent lesions, presenting as asymptomatic sub-epithelial
firm round nodules [5]. In the oral cavity, the mean size at presentation is 2 cm, with the
majority of lesions being treated before 3 cm in size [1]. GCTs are nondescript on imaging
and, especially for larger lesions, may be interpreted as an invasive lesion on computerised
tomography (CT) or magnetic resonance imaging (MRI) [6]. Tumours larger than 5 cm
in diameter are suspicious for malignant transformation [7]. Narrow margin excision is
the recommended treatment. Recurrence rates have been cited as 20% for incompletely
excised lesions and at 2–8% of lesions with surgically clear margins, with recurrence likely
the result of residual satellite cells/tumour extensions [8,9].
Grossly, GCTs are tan/pale-coloured, rubbery, and poorly circumscribed nodules
without a capsule. Histologically, they are composed of larger-than-average polygonal- or
lozenge-shaped cells of varying size, with abundant cytoplasmic eosinophilic granules and
small eccentric nuclei. The granules are periodic acid Schiff (PAS)-positive and diastaseresistant [10] and stain positively with Luxol fast blue [1]. Tumour cells are arranged in
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clusters or sheets with interspersed thin/scant bands of connective tissue. The periphery
of the tumour is poorly delineated, sometimes appearing to merge both with the overlying
epithelium and with the underlying skeletal muscle, giving an infiltrative appearance.
Additionally, there are often detached clusters of cells that can be found a distance from the
bulk of the tumour, likely representing tumour extensions rather than budding lesions [1].
Reports of the presence of small nerves at the periphery of lesions suggest an association
between GCTs and perineural cells and may imply occurrence following axonal injury [1].
Nearly 50% of cases show evidence of pseudoepitheliomatous hyperplasia, which may be
mistaken for squamous cell carcinoma (SCC) by a pathologist unfamiliar with the lesion,
confounded by the rarity of GCTs and the relatively high incidence of SCC [11,12].
GCTs were first described by Weber and Virchow in 1854 [6]. Abrikossoff theorised
that they arose from myoblasts of the underlying skeletal muscle and named the tumour
myoblastenmyome or myoblastoma [1]. Electron microscopy (EM) and immunohistochemical studies ruled out myogenous differentiation and were suggestive of a possible
histiocytic origin, a possible common precursor to schwannomas, or undifferentiated mesenchymal precursors of fibroblasts that had phagocytised cellular debris [13–17]. Several
studies supported neural sheath cell differentiation [9,16–19].
In contrast to the cell markers suggesting a neural origin, there has also been suggestions of an endomesenchymal origin. Gurzu found that GCTs expressed macrosialin
(CD68), CD117 (c-kit), and RET [9]. GCTs have also been shown to express CD63, LC3
(microtubule-associated protein 1 light chain 3, a specific marker of autophagy) and antigenpresenting cell marker HLA-DR [20–22]. HLA-DR and CD68 immunoreactivity suggest an
antigen-presenting cell (APC) phenotype for GCTs. Recently, novel inactivating mutations
in ATP6AP1 and ATP6AP2 genes (associated with endosome acidification) have been
identified in 72% of GCTs in a study by Pareja et al. [23]. It is theorised that changes in
endosomal function result in altered cell signalling, giving GCTs oncogenic properties [23],
providing evidence of a mutation that likely contributes to an APC phenotype of GCT.
Additionally, considering the available evidence provided by IHC, it is not clear if GCTs
are true neoplasms or reactive in nature.
HLA-DR, CD68, CD163, CD40 and CD11c are proteins expressed by APCs in executing
their functions [24–31], while S100 protein, SOX10, NSE and GAP43 are proteins typically expressed by neural tissue, neural tumours and tissues of neural crest origin [32–36]. Growth
associated protein 43 (GAP43) or neuromodulin is an intracellular growth-associated protein that has a critical role in guiding axonal growth and regulating neural cytoskeleton
organisation and transduction of intra- and extra-cellular growth of neurites. It is inducible following nerve injury and plays a role in the new synapse formation of neural
networks [35]. There are no prior reports investigating GAP43 expression in GCTs.
This study aims to differentiate an antigen-presenting cell (APC) phenotype from a
neural tissue phenotype in GCTs using immunohistochemistry (HLA-DR, CD68, CD163,
CD40 and CD11c for APC), and polymerase chain reaction and to compare this expression
profile with schwannomas. Using RT-qPCR, we investigated RNA expression for nestin,
SOX2, SOX9, SOX10, NF2, beta tubulin-III and glial fibrillary acidic protein (GFAP)—all
proteins that are variably expressed by neural-crest-derived tissue and Schwann cells, in addition to CD68, beta tubulin-3 (a marker for neural tissue) and beta-actin as control [37–43].
2. Results
2.1. Demographics
The mean age for patients diagnosed with a biopsy-proven GCT was 41.4 ± 13.1. GCTs
were most prevalent in the fourth to sixth decades of life, with 6 cases diagnosed in the
fourth and fifth decades and 7 in the sixth decade. The mean age for patients with a biopsyproven schwannoma was 25 ± 9. Lesions were most prevalent in the third decade of life.
There were 14 cases of GCTs in females and 9 in males, giving a female:male ratio of 1.56:1.
There were 8 cases of schwannomas in males and 2 in females, with a male:female ratio
of 4:1. The most common location for GCTs was the dorsal tongue, with 16/23 lesions or
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69.5% of cases. The mean diameter of the lesions was 10.1 mm, with a range of 5 to 20 mm.
Lesions were treated by excisional biopsy, although in most cases, the deep margins were
positive. Despite this, no recurrences or relapses were recorded. There was no obvious
anatomical site predilection for schwannomas (Table 1).
Table 1. Demographics and site of biopsy.
Granular Cell Tumours
Case No.

Age

Sex

Site

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23

41
33
15
43
20
36
48
50
37
55
39
21
52
48
46
35
63
55
37
21
56
58
43

Female
Female
Female
Male
female
Male
female
Male
female
female
female
female
male
male
male
female
female
female
male
female
male
male
Female

midright dorsum of tongue
dorsum of tongue
dorsum of tongue
dorsum of tongue
right tongue
dorsum of tongue
left posterior hard palate
dorsum of tongue
left lateral border of tongue
right palatal mucosa
dorsum of tongue
right dorsum of tongue
right lateral border of tongue
right dorsum of tongue
right dorsum of tongue
right dorsum of tongue
left dorsum of tongue
left dorsum of tongue
dorsum of tongue
right lateral border of tongue
dorsum of tongue
right lateral ventral tongue
left dorsal tongue

Schwannomas
Case No.

Age

Sex

Site

1
2
3
4
5
6
7
8
9
10

28
21
23
41
16
37
22
15
16
31

Male
Male
Male
Male
Female
Female
Male
Male
Male
Male

buccal mucosa 37
left dorsum of tongue
right tip of tongue
left buccal mucosa
*** oral cavity
lower lip mucosa
lower lip mucosa
left buccal vestibule
dorsum of tongue
Upper lip

*** Site of biopsy was unspecified, anatomically from the oral cavity.

2.2. Immunohistochemistry
Immunohistochemical staining results are illustrated in Figures 1 and 2.
S100 staining: S100 immunoreactivity was identified in both the cytoplasm and the
nucleus of both GCTs and schwannomas, although nuclear staining was found to be greater
than that of cytoplasm. In the spindle cells of schwannomas, the staining was punctate
with bands of higher staining intensity in direct proximity to the nucleus, while cytoplasm
staining of GCTs was more diffused. Nearly all granular cells of GCTs and spindle cells
of schwannomas were found to stain, with little to no variability in the staining intensity
(Figure 1A,B).
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punctate pattern and minimal diffuse cytoplasmic staining. Within a given section, granular
cells tended to either demonstrate more punctate or more diffused staining patterns.
Staining of the Schwannomas was considerably different from that of GCTs. All
positive spindle cells demonstrated diffuse cytoplasmic staining, and a punctate pattern
was not appreciated. Spindle cells found in the densely populated Antoni A areas were
found to stain with high intensity. In contrast, the spindle cells of the Antoni B areas
were either negative for GAP43 reactivity or stained with low to moderate intensity in less
than 50% of the cells. This gave a patchy appearance to the Schwannoma GAP43 sections
(Figure 1G,H).
HLA-DR: GCTs and schwannomas had similar immunoreactivity for HLA-DR. Staining was mostly restricted to the cytoplasm, with some nuclei appearing to stain positive
for GCTs. Staining patterns were punctate on a diffuse background for both tumours.
Nearly all granular cells of GCTs and spindle cells of Schwannomas were stained with high
intensity, with minimal variability (Figure 2A,B).
CD68: CD68 immunoreactivity was restricted to the cytoplasm of both GCTs and
schwannomas. GCT cells were stained with a light diffuse punctate pattern. Schwannoma staining was variable: one case was void of any appreciable staining for CD68
immunoreactivity, while the remaining 9 cases had low to moderate staining (Figure 2C,D).
CD163: Schwannomas were positive for CD63, with high intensity in all sections,
while GCT immunoreactivity was absent. Schwannoma staining was punctate for all cells,
and staining was restricted to the cytoplasm (Figure 2E,F).
CD40 and CD11c: Schwannomas and GCTs had no CD40 and CD11c immunoreactivity.
Semiquantitative analysis using manual scoring: Table 2 shows the cumulative
scores for a percentage of cells stains and stain intensity, respectively, for both GCTs
and schwannomas. A contingency table was constructed with the ordinal variable percentage cells staining as the x-variable and staining intensity as the y-variable. A linearby-linear association test was completed. The p-value <0.0000000000000002 identifies that
the two variables are almost perfectly correlated. We rejected the null hypothesis that
there is no association between the variables’ percent cells stained and cell stain intensity.
Assuming the correlation between variables, we chose to complete further analysis using
only the ordinal variable for staining intensity and could extrapolate these findings to
percent cells staining.
Table 2. Mean DAB stain intensity and percentage of cells staining in GCTs and schwannomas.
IHC
Antibody
S100
NSE
SOX10
GAP43
HLA-DR
CD68
CD163
CD40
CD11c

GCT
Schwannoma
GCT
Schwannoma
GCT
Schwannoma
GCT
Schwannoma
GCT
Schwannoma
GCT
Schwannoma
GCT *
Schwannoma
GCT
Schwannoma
GCT
Schwannoma

Absent

Low

Medium

High

1
1
22 *
23
10
23
10

4
6
-

3
6
2
4
6
4
17
3
1
-

23
10
20
22
10
21
6
17
6
6
9

* Case 2 of GCT did not have a section for CD163 IHC.

0
(0%)

1
(>0≤50%)

2
(>50%)

1
1
22 *
23
10
23
10

3
6
-

23
10
23
10
22
10
23
7
23
10
23
3
10
-
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For each antibody used in this report, a chi-squared table was constructed using the
ordinal variable (staining intensity) as the x-axis and nominal variable (cell type) as the
y-axis. Given that we are performing multiple hypothesis tests, a Bonferroni correction
was applied. CD40, CD11c, and S100 antibody scoring were identical between GCTs and
schwannomas.
There was no statistical difference between the staining intensity for the antibodies
SOX10 (p = 0.5), GAP43 (p = 0.03), and HLA-DR (p = 0.4). Significantly higher stain
intensity was identified in GCTS for NSE (p = 0.000008) and CD68 (p = 0.0001). CD163 had
significantly higher stain intensity in schwannomas (p = 0.00000007).
An additional Cochrane-Armitage test was completed to compare the cell staining
intensity across all variables for GCTs and schwannomas. The staining intensities were
compiled into a single chi-squared table. A significant difference was identified between
the overall staining intensities for GCTs and schwannomas (α = 0.05, p = 0.000004).
No correlation was found between the expression profiles of specific markers and
clinical characteristics such as the size or site of GCTs.
Q-score analysis obtained from Qupath Bioimage analysis: QuPath was used to
digitally identify cells with positive staining, which were then further stratified into low,
medium and high staining intensities. It became apparent that the distribution of H-score
may follow a non-Gaussian distribution; however, given the low case count, it was difficult
to perform an analysis of variance. Therefore, both Student’s t-test for Gaussian distribution
and Welch’s t-test for non-Gaussian distribution were performed. A Bonferroni correction
was applied with m = 4 (4 tests), resulting in αbonferroni = 0.05/4 = 0.0125. Comparisons of
H-score between GCT and schwannoma for GAP43, HLA-DR, CD68 and CD163 antibodies
are demonstrated in Figure 3.
Digital scoring (H-score) was compared with the manual scoring intensity of cell
staining using Pearson’s correlation coefficient and Pearson’s correlation for continuous
variables (t-test). The results are summarised in Table 3. There was a near-perfect correlation
between the manual scoring of cell staining intensity and the H-score derived from digital
analysis using QuPath. A Bonferroni correction was not applied as the p-values for all
analyses were extremely low.
2.3. Summary of Cq Value Obtained Using RT-qPCR
RT-qPCR was used to detect the presence of mRNA. Statistical analysis was not
performed, and results are observational only. Six samples showed housekeeping gene
amplification and were used for additional target gene measurement. Cases 18 and 23
showed the lowest Cq value, indicating a relatively high level of expression, while Cases 1,
3, 8 and 15 showed low expression.
CD68 transcript was identified in 5/6 specimens subjected to RT-qPCR. Case 1 did not
show CD68 amplification, despite staining densely positive in all granular cells using IHC.
The other cases had detectable CD68 expression.
With the exception of Case 23 and NTC, none of the other cases showed detectable
SOX2, SOX9, SOX10, NF2 or nestin expression. Cases 18 and 23 were positive for BTub3
expression, while all others were negative. No cases showed SOX2 or GFAP mRNA
presence (Tables 4 and 5).
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0.0125, p = 0.0006); ### p ≤ 0.001.
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Table 3. Summary of the comparison of cell stain intensity using manual semiquantitative scoring
and H-score derived from QuPath.
Antibody

Correlation (r)

95% CI

p-Value

All tumours
GCTs only
Schwannomas only
GAP43
HLA-DR
CD68
CD163

0.906
0.903
0.9
0.92
0.961
0.989
0.979

0.827–0.949
0.767–0.961
0.759–0.960
0.689–0.981
0.841–0.991
0.951–0.997
0.911–0.979

0.000000000000001
0.00000005
0.00000007
0.0002
0.000009
0.00000007
0.0000008

Table 4. Summary of RNA concentration and B-actin and CD68 amplification cycles.
Case

RNA Concentration (µg/mL)

B-Actin Reactivity (Cq Value)

CD68 Reactivity (Cq Value)

1
3
6
7
8
15
16
17
18
22
23
NTC

6.5
17.4
4.24 *
2.88 *
5.7
7.4
Low *
2.2 *
10
4.16 *
6.5

34.70
37.38

37.15

36.94
34.53

35.96
37.12

29.71

32.53

28.89
-

25.60
-

* = RNA concentration insufficient to proceed with RT-qPCR. - = no amplification.

Table 5. Summary of Cq values for Case 23.
Gene

Cq Value

CD68
Nestin
SOX2
SOX9
SOX10
NF2
GFAP
Beta Actin
Beta TUB3

29.60
39.02
36.18
38.01
37.14
28.89
36.72

- = no amplification.

3. Discussion
The current understanding is that GCTs represent a tumour originating from Schwann
cell lineage or differentiating into a Schwann cell phenotype [1], although a number of
different tissues have been considered as an origin, including myoblasts [1], fibroblasts [13],
histiocytes [14] and endomesenchymal cells [9]. A Schwann cell line of differentiation
is supported by the similarity of their IHC profile for markers of neural crest cells and
neuroectodermal origin, including SOX10, S100 and NSE.
GCTs and schwannomas have significantly different expressions of the lysosomal
marker CD68, with GCTs staining strongly and diffusely and schwannomas staining weakly
in only a small number of cells. CD68 expression supports a possible APC phenotype.
Additional evidence that the granular appearance of GCTs results from lysosomes is
supported by work identifying mutations of the gene coding for accessory proteins of H+ATPase, ATP6AP1 and ATP6AP2, providing evidence of the abnormal lysosome content of
the granular cells [23]. The finding of this genetic mutation of GCTs suggests that they are
true tumours and not reactive lesions.
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3.1. Protein Expression Supporting an NCC Origin of GCTs
Polyclonal S100 is one of the most commonly used antibodies employed by pathologists to assist with differentiating spindle cell lesions from NCC and non-NCC origins. The
S100 polyclonal antibody used in this investigation has the highest specificity for S100B.
There is copious evidence to suggest that neural and glial cells express a high level of S100
protein, particularly S100B, in their healthy state [44]. It is also generally accepted that all
benign and most malignant tumours with NCC differentiation express S100 protein [44]. In
contrast to the presumed specificity of S100B, a variety of tumours and cells originating
from all germ layers can be induced to express S100 proteins, particularly S100A8, S100A9,
S100A12 and S100B, as a result of oxidative stress and tissue inflammation [45]. The strong
intensity of SOX10 immunoreactivity provides additional evidence of an NCC origin or
NCC differentiation and is emerging as a more specific marker of NCC origin than S100. It
is interesting to note that one case in this study was non-reactive for SOX10 immunoreactivity while staining with strong intensity in most cells for S100. Negative immunoreactivity
to SOX10 was confirmed by repeating SOX10 IHC on a second section of this particular
case. We considered excluding this case from our investigation but ultimately decided
that the tissue was still interpretable for histopathology. The explanation for the lack of
SOX10, in the context of the remainder of the staining profile of this case, could either be
that during tumourigenesis, the tumour lost SOX10 expression or that the lack of SOX10
staining was a consequence of freezing during tissue transport. SOX10 has been shown
to be expressed in virtually all BPNST; however, there are several reports identifying the
absence of SOX10 staining in MPNST in 30% of tumours, which can be problematic for
pathologists in diagnosing malignant spindle cell lesions [46]. We were unable to find any
reports of either peripheral benign or malignant GCTs that did not express SOX10 but
expressed S100 protein. Of note, central nervous system GCTs, which are presumed to
develop from an astrocyte origin and have a virtually identical histological appearance
to peripheral GCTs, were found to stain negatively for SOX10 [47]. In contrast, there
are several case reports identifying GCTs found to be negative for S100 but positive for
SOX10, both from the oral cavity and other anatomical sites. It is unclear if these tumours,
referred to as primitive GCTs, are derived from mesenchyme of an NCC origin that differs
from traditional GCTs or if these tumours have lost S100B expression [48]. While both
GCTs and schwannomas stained positive for NSE, providing support of a NCC origin, an
interesting finding of this investigation was that GCTs stained with higher intensity in a
greater percentage of cells than schwannomas for NSE. This may indicate that GCTs have
a higher metabolic demand than schwannomas as there are multiple reports that NSE is
upregulated in both tumours derived from NCC and non-NCC-derived tumours during
inflammation and hypoxic stress [34,49–51].
This report is the first to identify the GAP43 immunoreactivity of GCTs. GAP43 is a
relatively newly discovered protein that appears to be a highly specific marker of neural
and glial tissues. Its role in glial cells has yet to be determined; however, there is evidence
to suggest it promotes the outgrowth of neurites during development and following nerve
injury in growth cone formation [36]. It is interesting to note that GAP43 is expressed
in repair Schwann cells and Schwann cell precursors but not in mature Schwann cells.
Its expression also occurs late, following nerve injury at 4 weeks, which suggests that its
expression occurs late in Wallerian degeneration following the clearance of myelin debris [7].
In contrast to S100 and SOX10, GAP43 expression is also retained by MPNST and has
recently been suggested to have a higher sensitivity and specificity for NCC-derived spindle
cell malignancies than either S100 or SOX10 [52]. Recent studies have identified GAP43
immunoreactivity in a variety of malignancies [53–55], calling into question the presumed
specificity of GAP43 and suggesting that it has additional yet-to-be-determined roles in
tumorigenesis. GAP43 immunoreactivity provides new evidence that GCTs originate from
the NCC and provides the strongest evidence yet that GCTs likely develop from Schwann
cells, suggesting that the granular cells of GCTs have a cell phenotype more similar to
repair Schwann cells or Schwann cell precursors than mature Schwann cells.
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Another finding in this report that has not been described is the architecture of schwannoma GAP43 staining. Immunoreactivity of the cell-rich Antoni A region was found to
stain with high intensity in most spindle cells, while the Antoni B region was found to
stain with low intensity in less than 50% of the spindle cells. Antoni B regions are generally
thought to be degenerated regions of schwannomas associated with inflammation such
as hyalinisation, fibrosis, mucin inclusion, thrombosis, and macrophage and lymphocyte
infiltration [56,57]. Greater staining of the Antoni A regions would suggest that GAP43
immunoreactivity and protein expression decrease as the spindle cells of schwannomas
begin to lose the architecture of Antoni A areas and transition to Antoni B areas. This
would also suggest that the granular cells of GCTs are more similar to the spindle cells
found in the Antoni A areas than the Antoni B areas.
3.2. Protein Expression Supporting an APC Phenotype
Collectively, the evidence from this investigation provides weak evidence of an APC
phenotype for GCTs. At the onset of our investigation, the function of the increased lysosome content of the granular cells was unknown, and it was unclear if GCTs were reactive
lesions or tumours. Consistent with other reports, this investigation identified strong
staining intensity in the majority of granular cells for the CD68 antibody, indicating that the
granules are lysosomes. CD68 is generally accepted as a cell marker for tissues with a phagocytic function, such as histiocytes, monocytes, giant cells, Kupffer cells, and osteoclasts, and
its expression is thought to be regulated by a macrophage-specific promoter gene [26,27]. It
had been theorised that lysosomes of GCTs may indicate a phagocytic function of GCTs
following nerve injury. The presence of an abnormal number of lysosomes has now been
explained by the work of Pareja et al., who have identified a novel mutation of the ATP6AP1
and ATP6AP2 genes coding V-ATPase accessory proteins, which have roles in endosome
acidification and transport [23]. These findings provide clear genetic evidence to explain
the intensity of CD68 immunoreactivity and confirm the theory that the accumulation
of lysosomes is a result of altered lysosomal transport and function. Additional support
of an APC phenotype for GCTs is the strong immunoreactivity for HLA-DR. HLA-DR
expression is associated with APCs, including B lymphocytes, activated T lymphocytes and
professional APCs (monocytes, macrophage and dendritic cells) [24]. We had theorised that
in combination with CD68 immunoreactivity, HLA-DR immunoreactivity could suggest
that GCTs may be reactive in nature and have a role in antigen presentation during the
innate immune response. This theory is disproven by genetic evidence that the lysosomes
of GCTs are non-functional and have negative reactivity for the costimulatory molecule
CD40, suggesting that GCTs cannot participate in T-cell activation [58]. Given that GCTs are
thought to have malignant potential, it is plausible that HLA-DR expression serves a role
in GCTs analogous to HLA-DR expression by melanomas [59]. In melanomas, HLA-DR is
thought to be associated with tumour-antigen presentation, tissue inflammation, and an
immune response against tumour cells and is a positive prognostic factor for survival [59].
A third explanation is that the presence of HLA-DR immunoreactivity may suggest an
epithelial–mesenchymal transformation, more indicative of tissue dedifferentiation and an
APC phenotype rather than serving a role in antigen presentation. Finally, a fourth possible explanation is that expression of HLA-DR indicates tissue inflammation as HLA-DR
expression has been reported in several different cell populations during tissue inflammatory responses [60–62]. HLA-DR immunoreactivity has not been previously described in
schwannomas, and, significantly, all schwannomas in this study were positive for HLA-DR.
While immunoreactivity of schwannomas to HLA-DR has not been reported, expression
of HLA-DR has been reported in gliomas and neuroblastomas, where it is thought to be
associated with increased tumour inflammation and worse patient outcomes [63].
The negative immunoreactivity of GCTs for CD163, CD40 and CD11c does not provide
support for an APC phenotype of GCTs. An interesting finding that has not been previously
reported was the strong intensity of schwannoma immunoreactivity for CD163. The
upregulation of CD163 in schwannomas could possibly be explained by a cell phenotype of
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the spindle cells of schwannomas, similar to the phagocytic phenotype of repair Schwann
cells, and also serve as a marker of an inflammatory process. In GCTs, we identified cells
with a dendritic appearance that had reactivity to CD163. This supports inflammation
within GCTs, which could result in HLA-DR expression, but does not provide support of
an APC phenotype for GCTs.
3.3. Interpretation of RT-qPCR Data
Surprisingly, SOX10 mRNA was only detected in one case (Case 23) and non-reactive
in 5/6 cases. The non-expression of SOX10 is in stark contrast to previously published
literature regarding GCT immunoreactivity to SOX10 and is inconsistent with the IHC
findings of this investigation. Given that findings from RT-qPCR are accepted to be more
sensitive and specific than IHC findings, this result is perplexing. One possible theory
is that SOX10 is a highly stable protein, such that very low levels of mRNA are required
to maintain adequate SOX10 levels for cell function. The level of SOX10 mRNA could
have been insufficient to be detected in 40 cycles of PCR. One other possible explanation is
that SOX10 mRNA was more susceptible to degradation than either CD68 or beta-actin.
Fragmented mRNA would still be detected using Qubit fluorescence, giving the impression
that there was a sufficient concentration of RNA for further work. Alternatively, it could be
a combination of both very low levels of SOX10 mRNA and mRNA degradation. Without
positive SOX10 reactivity, it is challenging to make any further conclusions regarding the
reactivity of nestin, SOX2, SOX9, SOX10, NF2 and GFAP.
3.4. Limitations of This Study
While digital analysis is likely more accurate than objective scoring methods and certainly seems to be better at detecting small differences in staining intensity, there are several
issues with whole slide analysis using QuPath, related to manual settings and developing
discriminatory algorithms for detection of cell boundaries, cytoplasm and nuclei.
In light of a strong body of evidence that GCTs are immunoreactive for SOX10, we
elected to interpret the absence of SOX10 amplification as inadequate SOX10 mRNA quality
despite PCR having a higher specificity and sensitivity than IHC techniques.
3.5. Future Work
It may be worthwhile investigating an NCC developmental phenotype of GCTs using
an alternative RNA isolation protocol. More work needs to be done to explore the variety
of lesions that can occur with a granular appearance. Specifically, it would be interesting to
assess for mutations of lysosome formation, acidification and transportation using gene
sequencing similar to the methods used to identify genetic mutations of ATP6AP1 and
ATP6AP2 in GCTs.
4. Material and Methods
4.1. Case Selection
Formalin-fixed paraffin-embedded tissues (FFPE) of 23 serial/consecutive cases of
benign GCTs and 10 cases of schwannoma 2006–2016 were retrieved from the archives of the
Department of Pathology, Schulich School of Medicine and Dentistry, Western University.
Malignant cases were not identified. Patient age, sex, and location of the lesion were
recorded. Patient demographics are shown in Table 1.
4.2. Immunohistochemistry (IHC)
Neural markers S100, SOX10, NSE and GAP43 and APC markers HLA-DR, CD68,
CD163, CD40 and CD11c were examined (Table 6); 5 µm tissue sections were obtained
from hydrated FFPE blocks. The Dako Autostainer Link 48 was used for automated IHC
staining of the S100, SOX10, NSE, HLA-DR, CD68 and CD163 antibodies. The slides also
had a standard positive control tissue array, and at least one negative control section of
each tumour type was utilised for each antibody.
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Table 6. Summary of the antibodies used for immunohistochemistry of GCTs and schwannomas.
Antibody

Manufacture/Cat
Number

Antibody Type

Constituent Tissue and Labelling Targets

Dilution

S100

Dako, Santa Clara CA
IR50461-2

Rabbit polyclonal

Neural tissues, S100B (strong) S100A1 and
S100A6 (weak)

Automated

NSE

Dako, Santa Clara CA
IR61261-2

Mouse monoclonal

Neural tissues, γ-enolase subunit

Automated

SOX10

Santa Cruz Biotech, Dallas
TX, sc-365692

Mouse monoclonal

Neural tissues, SOX10 transcription factor

Automated

GAP43

Bio-Techne Canada,
Oakville On, NB300-143

Rabbit polyclonal

Regenerating neural tissues/growth cones,
GAP43 intracellular growth
protein/membrane protein

1/5000

HLA-DR

Dako, Santa Clara CA
MO74601

Mouse monoclonal

APCs and lymphocytes, Alpha-chain of
HLA-DR cell surface receptor

Automated

CD68

Dako, Santa Clara CA
GA61361-2

Mouse monoclonal

Macrophage, lysosomal-associated
membrane proteins

Automated

CD163

Vector laboratories,
Burlingame CA
VP-C374

Mouse monoclonal

Macrophage, hemoglobin-scavenger receptor

Automated

CD40

Abcam, Toronto ON,
ab13545

Rabbit polyclonal

APCs, cell surface innate immune response
costimulatory protein

1/1000

CD11c

Abcam, Toronto ON,
ab52632

Rabbit monoclonal

APCs, cell surface fibrinogen receptor

1/300

Sections of GCTs and schwannomas, in addition to appropriate positive controls
(schwannoma for GAP43 and tonsil for CD40 and CD11c) and negative case controls, were
used in the procedure. Antigen retrieval was performed in citrate buffer pH6 using a
decloaking chamber (Biocare Medical, Pacheco, CA, USA). Sections were cooled, washed in
phosphate-buffered saline (PBS), placed in a humidified chamber and blocked for 30 min
with 2.5% horse serum. Rabbit anti-human Gap43 antibody (1/5000 dilution, cat no.
NB300-143 Bio-Techne Canada Corporation, Oakville, ON, Canada), rabbit anti-human
CD40 antibody (1/1000 dilution, Cat no. ab13545 Abcam, Toronto, ON, Canada) and rabbit
anti-human CD11c (1/300 dilution, Cat no. ab52632 Abcam, Toronto, ON, Canada) were
applied. The primary antibodies were incubated overnight at 4 ◦ C with a negative control.
On day 2, the sections were washed and then incubated with a secondary antibody. GAP43 and CD40 slides were incubated with immPRESS anti-rabbit IgG (Cat No.
VECTMP540150 MJS Biolynx, Brockville, ON, Canada) for 30 min at room temperature.
CD11c sections were incubated with Avidin-Biotin Complex VECTASTAIN Elite ABC-HRP
Kit (Ready-to-Use) (Cat no. PK-7200, Vector Laboratories, Burlington, ON, Canada) at
room temperature for 30 min. To visualise the staining, sections were incubated with a
3,30 -diaminobenzidine (DAB) peroxidase substrate kit (Cat no VECTSK4100 MJS Biolynx,
Brockville, ON, Canada). The sections were counterstained with Harris hematoxylin (Leica
Biosystems Inc., Concord, ON, Canada).
4.3. Evaluation of Immunostaining
All slides were examined under light microscopy and scored according to the semiquantitative methods described below. In addition to manual scoring, 5 randomly selected
cases of both GCTs and schwannomas for the antibodies GAP43, CD68, HLA-DR, CD163
were subjected to digital analysis using QuPath, an open software platform for bioimage
analysis, a free open source digital bioimage analysis software that has been validated for
its accuracy and reproducibility of results [64,65], available at https://qupath.github.io/
(accessed on 1 June 2020).
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4.3.1. Manual IHC Scoring
Each IHC slide was evaluated under light microscopy, utilising the semiquantitative
analysis described below. Only the large polygonal cells that matched the histological
description of the granular cells of GCTs were assessed. For schwannomas, analysis was
restricted to tumour cells within the capsule. The scoring criteria consisted of an objective
analysis of the average number of cells that stained positive within the representative
high-power section. Staining intensity was subjectively scored relative to the appropriate
positive controls. The scoring system used was as follows: for staining intensity: 0 = absent;
1 = weak; 2 = moderate; 3 = high; and for percentage of cells stained: 0 = 0%; 1 = 0–50%;
2 > 50%.
4.3.2. IHC Digital Analysis
Five cases each of GCTs and schwannomas underwent high-resolution whole slide
imaging using an Aperio slide scanner for the antibodies GAP43, HLA-DR, CD163 and
CD68. Images were then uploaded to QuPath (v0.1.2). Images stained with the same IHC
antibody (5 cases of GCT and 5 cases of schwannoma) were grouped to create a multislide project). For each of the four multi-slide projects, the same workflow was followed.
Automated cell detection was completed by identifying cell nuclei via the hematoxylin
optical density and nucleus size parameters. Positive cell detection was determined by
the mean DAB optical density of the cell. A detection classifier was trained by adjusting
the DAB optical density classification for low, medium and high intensities after visually
selecting cells that had objectively low, medium and high staining intensities as a reference.
Data was reported as a percentage of cells detected and also as an H-score. H-scores range
from 0–300 and are calculated by 3× percentage of strong staining + 2× percentage of
moderate staining + 1× percentage of weak staining (total ranging from 0 to 300).
4.4. Protocol for RT-qPCR
RNA was extracted from GCT FFPE tissue blocks and cDNA synthesised for the
detection of CD68, nestin, SOX2, SOX9, SOX10, NF2, GFAP, beta-actin and B-Tub3.
4.4.1. Tissue Preparation
Eleven FFPE blocks were assessed to have sufficient tumour volume to proceed with
tissue isolation prior to RNA extraction. The corresponding H&E slide was examined under
light microscopy to identify a region of the tumour that demonstrated typical features
of GCTs, and non-tumour cells were excluded. A 1 mm punch biopsy of the FFPE block
was obtained at a depth of 1 mm. The tissue plug was then placed into 1.5 mL collection
tubes; 5 µm tissue sections of each case were obtained from hydrated FFPE blocks to verify
that the site of the punch biopsy was representative of the tumour. H&E staining of these
sections was completed, and the sections were visualised under the microscope, confirming
the accuracy of the tissue punches were restricted to tumour tissue in all 11 cases.
4.4.2. RNA Isolation
The specimens were deparaffinised, and RNA isolation was completed using the
High Pure FFPE RNA Micro Kit (Roche Applied Sciences, Mannheim, Germany, Catalogue
number: 04823125001). Tissue lysis buffer and 10% sodium dodecyl sulfate were added
to the tissue plugs, followed by protein kinase K solution. The tubes were then agitated
and incubated at 55 ◦ C for 3 h. The cell lysate was extracted and placed into an RNAbinding spin column. Each tube was then spun on a centrifuge, and the flow-through was
discarded. DNase solution was added, and the tubes were allowed to incubate for 15 min
at room temperature. The RNA was then purified by rinsing the RNA with a series of
buffer solutions, centrifuging at 8000× g for 5 min and discarding the supernatant each
time. Elution buffer was added and allowed to incubate at room temperature for 1 min.
The RNA spin column was then centrifuged at 8000× g for 1 min. The RNA eluate was
collected and used for RNA quantification.
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4.4.3. RNA Quantification
RNA concentration of the RNA eluate was measured using the Qubit Quan-iT RNA
BR assay kit (Thermo Fisher Scientific Carlsbas, CA, USA, catalogue number Q10210) and
a Qubit fluorometer. Qubit RNA BR reagent was diluted to 1:200 in Qubit RNA BR buffer;
198 µL of prepared Qubit working solution and 2 µL of RNA eluent were added to clear
0.5 mL tubes. An additional 2 tubes were prepared by adding 10 µL Qubit standards to
190 µL of working solution and were used to calibrate the fluorometer to the standards. The
concentration of RNA was then referenced to the prepared standards. RNA concentration
in µg/mL was determined using the formula: RNA concentration = QF x (200/x)
4.4.4. cDNA Synthesis and RT-qPCR
In total, 6 of 11 samples yielded sufficient RNA to proceed with complementary
DNA (cDNA) synthesis. Isolated RNA was transcribed to cDNA using the iScript cDNA
Synthesis Kit (Bio-Rad Laboratories, Inc., Hercules, CA, USA, catalogue number: 1708890).
For each sample, 20 µL of cDNA mixture was prepared (4 µL 5x iScript reaction mix
containing reverse transcriptase, 100 ng RNA and balance of the volume as nuclease-free
H2 O). RT-qPCR reactions were carried out in 96-well arrays (Hard-Shell® Low-Profile
Thin-Wall 96-Well Skirted PCR Plates, Bio-Rad, HSP-9601). Each well contained 10 µL
RT2 SYBR Green qPCR Mastermix (Bio-Rad, 330501), 2 µL primer, 1 µL cDNA mix and
7 µL nuclease-free water. A no-template control (NTC) was used, which contained 8 µL
of nuclease-free water and no cDNA. The array was constructed with case number as
the y-axis and RT-qPCR was completed over a total of 40 cycles of amplification in CFX
Connect (Bio-Rad Laboratories, Mississauga, ON, Canada). The assay information is shown
in Table 7.
Table 7. Summary of primers employed in RT-qPCR.
Gene Assay

Vendor

Cat Number

Amplicon Length

Exon-Spanning

CD68
NESTIN
SOX2
SOX9
SOX10
NF2
GFAP
Beta-Actin
Beta-TUB3

QIAGEN
QIAGEN
QIAGEN
QIAGEN
QIAGEN
QIAGEN
QIAGEN
QIAGEN
QIAGEN

QT00037184
QT01015301
QT00237601
QT00001498
QT01670326
QT00030191
QT00081151
QT01680476
QT00083713

73 bp
75 bp
64 bp
111 bp
145 bp
148 bp
96 bp
104 bp
78 bp

Y
Y
N
Y
Y
Y
Y
Y
Y

4.5. Statistical Analysis
Given that percent cells stained and stain intensity are both ordinal variables, a linearby-linear association test was completed to assess the correlation of the two variables
between the pooled GCT and schwannoma data, resulting in a near-perfect correlation.
Due to the high level of correlation, only stain intensity was used for further statistical
analysis, and results comparing staining intensity between GCTs and schwannomas could
be extrapolated to the percentage of cells staining. A Cochrane-Armitage test for trend,
using a generalised chi-squared test, was used to compare the overall staining intensities
for GCTs versus schwannomas and for the 9 IHC antibodies used with the ordered nominal
variable (intensity) and a non-ordered nominal variable cell type. As multiple hypotheses
were applied to the same data set, a Bonferroni correction was applied. Three of the IHC
stains, S100, CD40 and CD11c, had no variability within their data set and were of equal
values between GCTs and schwannomas, so they were not used when calculating the
Bonferroni correction with m = 6 (αbonferroni = 0.5/6).
Using the data generated by digital analysis, Student’s t-test and Welch’s t-test correction were performed to assess for differences between the H-scores of GCTs and schwannomas. Again, a Bonferroni correction was used with m = 4 (Corrected.αbonferroni 0.5/4). A
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Pearson correlation coefficient test was completed, comparing the H-scores and the staining
intensity for each individual IHC antibody.
5. Conclusions
This study provides new evidence of an NCC origin or path for GCTs, probably of
Schwann cell lineage, as supported by IHC immunoreactivity of GAP43 (significantly) as
well as S100 protein, SOX10 and NSE. The expression of HLA-DR and CD68 supports the
induction of an APC phenotype in a nerve sheath tumour. Because of the strong evidence
that GCT tumourigenesis is along the NCC lineage, we suggest that GCTs be added to
the peripheral nerve sheath tumour classification system. The term “granular cell nerve
sheath tumour” might be more descriptive of this relatively rare lesion, and an appropriate
immunophenotypic and molecular panel (including GAP43) should be implemented in the
diagnosis of GCTs.
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